3-ethyl-4-methyl-quinoline | 79398-82-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-ethyl-4-methyl-quinoline
• 英文别名: 3-Aethyl-4-methyl-chinolin；3-Ethyl-4-methylquinoline
• CAS: 79398-82-6
• 化学式: C₁₂H₁₃N
• mdl: MFCD18448263
• 分子量: 171.242
• InChiKey: PATWMCROCFNSMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 、 tin(ll) chloride 作用下， 生成 3-ethyl-4-methyl-quinoline
  参考文献：
  名称：

  Byvanck, Chemische Berichte, 1898, vol. 31, p. 2153

  摘要：

  DOI：

文献信息

• Inhibitors of MALT1 and uses thereof
  申请人：Cornell University

  公开号：US11248007B2

  公开（公告）日：2022-02-15

  Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-κB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

  本文提供了抑制 MALT1 的化合物，MALT1 是一种蛋白质，其活性在某些癌症（如活化 B 细胞弥漫性大 B 细胞淋巴瘤（ABC-DLBCL））中负责组成型 NF-κB 信号转导。此外，还提供了包含所述化合物的药物组合物和试剂盒，以及通过施用所述化合物和/或组合物，用所述化合物治疗受试者MALT1相关疾病和失调（如癌症）的方法。
• The Synthesis of 3-Alkyl-4-methylquinolines¹
  作者：A. Langley Searles、H. G. Lindwall

  DOI：10.1021/ja01210a025

  日期：1946.6
• OHTA, KAZUKO;SHIMIZU, HIROKO;NOMURA, YUJIRO, NIPPON KAGAKU KAJSI,(1989) N, S. 846-854
  作者：OHTA, KAZUKO、SHIMIZU, HIROKO、NOMURA, YUJIRO

  DOI：——

  日期：——
• SHARMA R.; PANDE R. K.; JAIN P.; JOSHI B. C., ARCH. SCI., 1981, 34, NO 1, 89-91
  作者：SHARMA R.、 PANDE R. K.、 JAIN P.、 JOSHI B. C.

  DOI：——

  日期：——
• INHIBITORS OF MALT1 AND USES THEREOF
  申请人：Cornell UNiversity

  公开号：US20200385405A1

  公开（公告）日：2020-12-10

  Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-κB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.